Page 303 - Drug Class Review
P. 303
Drug Effectiveness Review Project
Alzheimer Drugs Authors: Areosa et al. 70 Year: 2005 Country: Multinational (Germany, France, Belgium, Sweden, UK, USA, Latvia). Funding for review NR; all included studies were funded by Merz Pharma KGaA, Frankfurt, Germany Study design: Systematic review of MEM trials Number of patients: Ranged from 60 – 579 To determine the clinical efficacy and safety of MEM for people with AD, or vascular or mixed dementia 7 placebo-controlled RCT studies were included: Ditzler 1991; Gortelmeyer 1992; MMM300 (Orgogozo) 2000; MMM500 (Wilcock) 2000; Pantev 1993; Reisberg 2000; Winblad 1999 Trials c
Final Report Update 1 Subgroups STUDY: FUNDING: DESIGN: AIMS OF REVIEW: STUDIES INCLUDED IN META-ANALYSIS TIME PERIOD COVERED: CHARACTERISTICS OF INCLUDED STUDIES: CHARACTERISTICS OF INCLUDED POPULATIONS: Alzheimer's Drugs
